Xarelto ( Rivaroxaban )

Order cheap Xarelto (Rivaroxaban) without dr prescription in the United States

In our USA pharmacy, you can buy Xarelto without a prescription, with delivery across the USA within 2‑5 days. Discreet and anonymous packaging.
Xarelto (rivaroxaban) is an oral, direct factor Xa inhibitor that acts as an anticoagulant by selectively blocking coagulation factor Xa, a key protein in the blood clotting cascade. By inhibiting both free and clot‑bound factor Xa and prothrombinase activity, it prevents thrombin generation and thrombus formation without requiring the cofactor antithrombin III.
Usual adult dose: For nonvalvular atrial fibrillation (NVAF), 20 mg once daily with the evening meal; reduce to 15 mg once daily if creatinine clearance ≤50 mL/min. For acute deep vein thrombosis (DVT) or pulmonary embolism (PE), 15 mg twice daily with food for the first 21 days, then 20 mg once daily with food. For extended VTE prevention or postoperative DVT prophylaxis, 10 mg once daily with or without food.
Dosage form: Film‑coated oral tablets (10 mg, 15 mg, 20 mg; also 2.5 mg for other indications).
Onset of action: Peak plasma concentrations are reached 2‑4 hours after oral administration; anticoagulant effect begins within 1‑4 hours.
Duration of action: Approximately 24 hours (elimination half‑life 5‑9 hours in healthy adults, up to 11‑13 hours in the elderly), supporting once‑daily dosing for most indications.
Alcohol consumption should be limited to light or moderate amounts; heavy alcohol intake may increase the risk of gastrointestinal bleeding and liver function abnormalities.
Most common side effects: bleeding complications including epistaxis, contusion, gingival bleeding, menorrhagia, and wound secretion.
Would you like to try Xarelto without a prescription?

General Information about Xarelto

• INN (International Nonproprietary Name): Rivaroxaban
• Brand names available in the USA: Xarelto® (Janssen Pharmaceuticals, Inc., a Johnson & Johnson company). Generic rivaroxaban tablets are available from multiple FDA‑approved manufacturers, including Aurobindo Pharma Limited, Lupin Pharmaceuticals, Inc., Macleods Pharmaceuticals Limited, Novadoz Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc., and others.
• ATC code: B01AF01
• Dosage forms and strengths: Film‑coated tablets: 2.5 mg, 10 mg, 15 mg, and 20 mg. Oral suspension: 1 mg/mL after reconstitution.
• Manufacturers in USA: Janssen Pharmaceuticals, Inc. (brand Xarelto®); generic manufacturers include Aurobindo Pharma Limited, Lupin Pharmaceuticals, Inc., Macleods Pharmaceuticals Limited, Novadoz Pharmaceuticals LLC, Teva Pharmaceuticals USA, Inc.
• Registration status in USA: Approved by the U.S. Food and Drug Administration (FDA) on July 1, 2011 (NDA 022406).
• OTC / Rx classification: Prescription only (Rx).

Mechanism of Action and Pharmacology

Rivaroxaban is a potent, oral, direct, competitive, and reversible inhibitor of coagulation factor Xa. It selectively binds to the active site of factor Xa with an inhibitory constant (Ki) of 0.4 nmol/L, achieving more than 10,000‑fold selectivity for factor Xa over other human serine proteases. Unlike indirect factor Xa inhibitors such as fondaparinux, rivaroxaban does not require antithrombin III as a cofactor. It inhibits both free factor Xa in plasma and factor Xa bound within the prothrombinase complex, thereby attenuating thrombin generation and subsequent fibrin clot formation. Rivaroxaban also inhibits clot‑associated factor Xa, which may contribute to its antithrombotic efficacy. Following oral administration, rivaroxaban is rapidly absorbed with peak plasma concentrations achieved in 2‑4 hours. The absolute bioavailability of the 10 mg dose is approximately 80‑100% and is not significantly affected by food; however, the 15 mg and 20 mg doses have reduced bioavailability when taken on an empty stomach (approximately 66% without food) and must be taken with food to ensure adequate absorption. Plasma protein binding is approximately 92‑95%, primarily to albumin. Rivaroxaban is metabolized via oxidative degradation by CYP3A4, CYP2J2, and CYP‑independent mechanisms, and via hydrolysis. Approximately one‑third of the dose is excreted renally as unchanged drug, one‑third as metabolites, and one‑third via the fecal route. The terminal elimination half‑life is 5‑9 hours in healthy young individuals and 11‑13 hours in the elderly.

Indications

• Reduction of risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation (NVAF).
• Treatment of acute deep vein thrombosis (DVT) and pulmonary embolism (PE).
• Reduction in the risk of recurrent DVT and PE following initial anticoagulation therapy. The 10 mg once‑daily dose is specifically indicated for extended prevention after at least 6 months of initial anticoagulation.
• Prophylaxis of DVT, which may lead to PE, in patients undergoing hip or knee replacement surgery.
• Prophylaxis of venous thromboembolism (VTE) in acutely ill medical patients at risk for thromboembolic complications.
• Reduction of risk of major cardiovascular events in patients with coronary artery disease (CAD) (2.5 mg twice daily in combination with aspirin).
• Reduction of risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularization due to symptomatic PAD (2.5 mg twice daily in combination with aspirin).
• Pediatric use: treatment of VTE and reduction in the risk of recurrent VTE following initial therapy in patients from birth to less than 18 years of age.

Important Warnings and Precautions

XARELTO CARRIES A BOXED WARNING FOR PREMATURE DISCONTINUATION AND SPINAL/EPIDURAL HEMATOMA. Premature discontinuation of any oral anticoagulant, including rivaroxaban, in the absence of adequate alternative anticoagulation significantly increases the risk of thrombotic events such as stroke and recurrent VTE. If rivaroxaban must be discontinued for a reason other than pathological bleeding or completion of a prescribed course of therapy, consider coverage with another anticoagulant. Epidural or spinal hematomas may occur in anticoagulated patients receiving neuraxial anesthesia or undergoing spinal puncture; these hematomas may result in long‑term or permanent paralysis. Risk factors include indwelling epidural catheters, concomitant use of other drugs affecting hemostasis, a history of traumatic or repeated epidural or spinal punctures, spinal deformity, or spinal surgery. Rivaroxaban can cause serious and potentially fatal bleeding. Promptly evaluate any signs or symptoms of blood loss. An agent to reverse the anti‑factor Xa activity of rivaroxaban (andexanet alfa) is available for life‑threatening or uncontrolled bleeding. Rivaroxaban is not recommended in patients with prosthetic heart valves or in patients with triple‑positive antiphospholipid syndrome due to a potentially increased risk of recurrent thrombotic events. Acute kidney injury may occur, particularly in patients with pre‑existing renal impairment, dehydration, or heart failure, and may be related to bleeding or hypotension.

At‑risk groups

• Elderly: No dose adjustment is required based solely on age; however, bleeding risk increases with age. The terminal elimination half‑life is prolonged to 11‑13 hours in elderly patients, but clinical significance is limited.
• Pregnancy: Limited available data are insufficient to inform drug‑associated risks. Rivaroxaban crosses the placenta and has been associated with hemorrhagic complications. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy testing is recommended for females of reproductive potential prior to initiating therapy.
• Breastfeeding: Rivaroxaban is present in human milk. Because of the potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
• Renal impairment: For NVAF patients with creatinine clearance (CrCl) ≤50 mL/min, the recommended dose is 15 mg once daily. Avoid use in patients with CrCl
• Hepatic impairment: Contraindicated in patients with moderate or severe hepatic impairment (Child‑Pugh B or C) and in patients with any hepatic disease associated with coagulopathy. Use with caution in mild hepatic impairment (Child‑Pugh A).
• Pediatric: Rivaroxaban is FDA‑approved for treatment and prevention of recurrent VTE in pediatric patients from birth to
• Low body weight: No dose adjustment is required based on body weight alone for the 10 mg dose. For NVAF, body weight alone is not a dose‑adjustment criterion; the 15 mg dose is used only when CrCl ≤50 mL/min, irrespective of weight.
• Prosthetic heart valves: Not recommended; safety and efficacy have not been established in patients with prosthetic heart valves.

Driving and alcohol

Rivaroxaban is not known to impair the ability to drive or operate machinery. Patients should be aware of signs and symptoms of bleeding (dizziness, weakness, fatigue) that may affect driving ability. Alcohol consumption should be limited to light or moderate amounts. Chronic heavy alcohol use may increase the risk of gastrointestinal bleeding and hepatic injury, and patients with significant alcohol intake should be monitored closely.

Dosage Instructions

• Nonvalvular atrial fibrillation (NVAF): 20 mg orally once daily with the evening meal. For patients with CrCl ≤50 mL/min, the dose is 15 mg once daily with the evening meal.
• Treatment of acute DVT and PE: 15 mg orally twice daily with food for the first 21 days, followed by 20 mg once daily with food for the remainder of the treatment period.
• Extended prevention of recurrent DVT and PE: 10 mg orally once daily with or without food, after at least 6 months of initial anticoagulation therapy.
• Prophylaxis of DVT following hip or knee replacement surgery: 10 mg orally once daily with or without food, starting at least 6‑10 hours after surgery once hemostasis has been established. Duration is 35 days for hip replacement and 12 days for knee replacement.
• Prophylaxis of VTE in acutely ill medical patients: 10 mg orally once daily with or without food, for 31‑39 days. Initiate during the hospitalization and continue after discharge.
• CAD or PAD: 2.5 mg orally twice daily with or without food, in combination with aspirin (75‑100 mg) once daily.
• Missed dose: For once‑daily dosing (10 mg, 15 mg, or 20 mg), if a dose is missed, take it as soon as remembered on the same day, and continue the next day with the usual schedule. Do not double doses. For twice‑daily 15 mg dosing (initial VTE treatment), if a dose is missed, take it immediately to ensure a total daily dose of 30 mg; two tablets may be taken at the same time.
• Administration: The 10 mg and 2.5 mg tablets may be taken with or without food. The 15 mg and 20 mg tablets must be taken with food to ensure adequate absorption and bioavailability. For patients unable to swallow whole tablets, tablets may be crushed and mixed with applesauce or suspended in water and administered immediately, followed by food. Crushed tablets may also be administered via nasogastric or gastric feeding tube.

Side Effects and Contraindications

Most common adverse reactions (incidence ≥5%): Bleeding events including epistaxis, contusion, gingival bleeding, menorrhagia, hematuria, and wound secretion. In clinical trials, the overall rate of bleeding events (major plus clinically relevant non‑major) with rivaroxaban 10 mg for extended VTE prevention was approximately 5‑10%.
Other common adverse reactions: Nausea, fatigue, syncope, pruritus, blister, and muscle pain.
Serious adverse reactions: Major bleeding events, including gastrointestinal hemorrhage, intracranial hemorrhage, intraocular hemorrhage, epidural/spinal hematoma, and fatal bleeding. Elevated liver transaminases and bilirubin. Hypersensitivity reactions, including anaphylaxis and angioedema. Stevens‑Johnson syndrome and drug reaction with eosinophilia and systemic symptoms (DRESS) have been reported rarely. Acute renal failure may occur secondary to hemorrhage or hypotension.
Absolute contraindications: Active pathological bleeding; severe hypersensitivity reaction to rivaroxaban (e.g., anaphylaxis); moderate or severe hepatic impairment (Child‑Pugh B or C) or hepatic disease associated with coagulopathy; concomitant use with drugs that are combined P‑glycoprotein (P‑gp) and strong CYP3A4 inhibitors or inducers in certain clinical situations; and triple‑positive antiphospholipid syndrome.

Drug Interactions

• Combined P‑gp and strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir): Significantly increase rivaroxaban exposure and may increase bleeding risk. Avoid concomitant use unless the potential benefit justifies the increased bleeding risk.
• Combined P‑gp and strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): Significantly reduce rivaroxaban exposure, potentially decreasing efficacy. Avoid concomitant use.
• Combined P‑gp and moderate CYP3A4 inhibitors (e.g., erythromycin, fluconazole): Clinically relevant increases in rivaroxaban exposure; however, no dose adjustment is required for most patients. Use with caution in patients with renal impairment.
• Anticoagulants and antiplatelet agents (e.g., warfarin, heparin, clopidogrel, prasugrel, ticagrelor, aspirin, NSAIDs, fibrinolytics): Coadministration increases the risk of bleeding. Dual or triple antithrombotic therapy should be limited to the shortest duration necessary and is recommended only for specific indications (e.g., CAD or PAD in combination with aspirin).
• SSRIs and SNRIs: These agents may further impair hemostasis and increase bleeding risk.
• Alcohol: Heavy alcohol consumption may increase the risk of gastrointestinal bleeding.
• Rivaroxaban does not meaningfully alter the pharmacokinetics of digoxin, atorvastatin, or midazolam.

Practical Advice

• Take Xarelto exactly as prescribed. The 10 mg dose for extended VTE prevention and postoperative DVT prophylaxis may be taken with or without food. The 15 mg and 20 mg doses must be taken with food.
• Do not discontinue Xarelto without consulting your healthcare provider. Stopping prematurely significantly increases the risk of stroke and other thromboembolic events. If therapy must be interrupted, a bridging strategy with another anticoagulant may be necessary.
• If you miss a dose of the once‑daily regimen (10 mg, 15 mg, or 20 mg), take it as soon as you remember on the same day. Do not double the next dose. For the twice‑daily 15 mg regimen (initial VTE treatment), take the missed dose immediately to ensure a total daily dose of 30 mg; two tablets may be taken at the same time if needed.
• Inform all healthcare professionals (including dentists) that you are taking rivaroxaban before any surgery, invasive procedure, or dental work. Rivaroxaban should generally be stopped at least 24‑48 hours before elective surgery, depending on bleeding risk and renal function.
• Watch carefully for signs and symptoms of bleeding: unusual bruising, prolonged bleeding from cuts, nosebleeds, bleeding gums, blood in urine or stool (red, pink, or brown urine; red or black/tarry stools), coughing up blood, vomiting material that looks like coffee grounds, heavy menstrual bleeding, or any bleeding that will not stop. Seek immediate medical attention if bleeding is severe or cannot be controlled.
• Watch for symptoms of spinal or epidural blood clot if you are receiving neuraxial anesthesia or spinal puncture: back pain, numbness or muscle weakness (especially in legs and feet), tingling, or loss of bladder or bowel control. These require emergency medical attention.
• Wear a medical identification bracelet or carry an anticoagulant alert card indicating that you are taking a blood thinner.
• Store at room temperature (20‑25°C / 68‑77°F) with excursions permitted between 15‑30°C (59‑86°F). Keep tablets in the original container, out of reach of children.
• Routine laboratory monitoring of coagulation parameters (PT, INR, aPTT) is not required. Anti‑factor Xa assays may be useful in specific clinical situations, such as emergency surgery or life‑threatening bleeding.
• An FDA‑approved reversal agent (andexanet alfa) is available for life‑threatening or uncontrolled bleeding. Activated charcoal may be used to reduce absorption in cases of recent overdose (within 2‑8 hours).

Alternative Medications

• Apixaban (Eliquis®): An oral direct factor Xa inhibitor dosed twice daily. Indicated for NVAF, VTE treatment and prevention, and post‑surgical thromboprophylaxis. Recent head‑to‑head trials suggest apixaban may be associated with less bleeding than rivaroxaban for VTE treatment.
• Edoxaban (Savaysa®): An oral direct factor Xa inhibitor dosed once daily. Indicated for NVAF and VTE treatment (following initial parenteral anticoagulation for 5‑10 days).
• Dabigatran (Pradaxa®): An oral direct thrombin (factor IIa) inhibitor dosed twice daily. Indicated for NVAF and VTE treatment (following initial parenteral anticoagulation for 5‑10 days).
• Warfarin (Coumadin®, Jantoven®): A vitamin K antagonist; requires regular INR monitoring and dietary vitamin K consistency. Preferred agent for patients with mechanical heart valves, severe renal impairment, or antiphospholipid syndrome.
• Low molecular weight heparins (e.g., enoxaparin, dalteparin): Injectable anticoagulants used for acute VTE treatment and prophylaxis; often used as bridging therapy when oral agents are interrupted.
• Fondaparinux (Arixtra®): An injectable indirect factor Xa inhibitor requiring antithrombin III for activity; used for VTE prophylaxis and treatment.

Clinical Efficacy

The clinical efficacy of rivaroxaban has been established across a broad spectrum of thromboembolic disorders. In the ROCKET AF trial for NVAF, rivaroxaban 20 mg (15 mg in patients with renal impairment) was non‑inferior to warfarin for the prevention of stroke or systemic embolism, with a comparable overall bleeding profile and a significant reduction in intracranial hemorrhage and fatal bleeding. In the EINSTEIN clinical program for acute DVT and PE treatment, rivaroxaban 15 mg twice daily for 21 days followed by 20 mg once daily was non‑inferior to standard enoxaparin‑to‑warfarin therapy for the primary efficacy endpoint (recurrent VTE or VTE‑related death), with a significant reduction in major bleeding in the EINSTEIN‑PE study. The EINSTEIN CHOICE trial demonstrated that extended‑duration rivaroxaban 10 mg once daily after 6‑12 months of initial anticoagulation reduced the risk of recurrent VTE by 74% compared with aspirin, without increasing major bleeding. The RECORD trials established the efficacy of rivaroxaban 10 mg once daily for VTE prophylaxis after total hip or knee replacement, showing superiority over enoxaparin without significantly increasing bleeding risk. The MAGELLAN and MARINER trials supported the use of rivaroxaban 10 mg once daily for VTE prophylaxis in acutely ill medical patients. In the COMPASS trial, low‑dose rivaroxaban 2.5 mg twice daily plus aspirin reduced major adverse cardiovascular events in patients with stable CAD or PAD, and the VOYAGER PAD trial extended this benefit to patients after lower extremity revascularization. Rivaroxaban has also been shown to be safe and effective in pediatric VTE treatment in the EINSTEIN‑Jr program. Together, these data support rivaroxaban as a versatile, evidence‑based oral anticoagulant for a wide range of indications.

Important:

Xarelto (rivaroxaban) is a prescription anticoagulant that must be used under the supervision of a qualified healthcare provider. A comprehensive medical evaluation, including assessment of renal function, hepatic function, and bleeding risk, is required before initiating therapy. Do not stop taking Xarelto without consulting your prescribing physician, as premature discontinuation significantly increases the risk of stroke and other thromboembolic events. This medication increases the risk of serious and potentially fatal bleeding; seek immediate medical attention if you experience any signs of unusual bleeding, including blood in urine or stool, coughing up blood, vomiting material that looks like coffee grounds, or any bleeding that will not stop. Notify your healthcare provider immediately if you experience back pain, numbness or muscle weakness in your lower body, or loss of bladder or bowel control, which may indicate a spinal hematoma. Xarelto is not recommended for patients with prosthetic heart valves or triple‑positive antiphospholipid syndrome. The 15 mg and 20 mg doses must be taken with food; the 10 mg dose may be taken with or without food. Inform all healthcare professionals, including dentists, that you are taking rivaroxaban before any surgical or invasive procedure. An FDA‑approved reversal agent (andexanet alfa) is available for life‑threatening or uncontrolled bleeding. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss the risks and benefits with their healthcare provider. Keep out of reach of children and never share your medication with others.

How to buy Xarelto no prescription U.S. Online Pharmacy